Literature DB >> 8305143

Flow cytometric DNA analysis of gastric cancer--correlation with histology and clinical outcome.

K S Suh1, S K Min.   

Abstract

Nuclear DNA content was analysed by means of flow cytometric measurements in 103 patients with gastric carcinomas, using paraffin-embedded archival tissue. DNA aneuploidy was found in 40 cases (38.8%). The mean DNA index of aneuploid tumors was 1.45(range 1.13 to 2.37). No significant association between ploidy and either age, sex, tumor location, size, stage, growth pattern, or histologic type was found. However, the incidence of aneuploidy was higher in high grade carcinomas than in low grade carcinomas; the incidence of aneuploidy was 10%, 68.8%, and 45.8% for Grade II, III, and IV carcinomas, respectively, as compared with Grade I carcinomas which were all diploid. On statistical analysis, Abnormal cellular DNA content was significantly correlated with high histologic grade (P < 0.005). Patients with aneuploid cancer (39.2%) had a poorer prognosis than those with diploid cancer (70.0%) based on (P < 0.01). The 2-year survival rate for advanced gastric carcinoma. Therefore, DNA ploidy might be a useful prognostic factor in cases of advanced gastric cancer.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8305143      PMCID: PMC3053718          DOI: 10.3346/jkms.1993.8.5.348

Source DB:  PubMed          Journal:  J Korean Med Sci        ISSN: 1011-8934            Impact factor:   2.153


  2 in total

1.  C-reactive protein as an adverse prognostic marker for men with castration-resistant prostate cancer (CRPC): confirmatory results.

Authors:  Renee C Prins; Brooks L Rademacher; Solange Mongoue-Tchokote; Joshi J Alumkal; Julie N Graff; Kristine M Eilers; Tomasz M Beer
Journal:  Urol Oncol       Date:  2010-03-06       Impact factor: 3.498

2.  Gross genomic damage measured by DNA image cytometry independently predicts gastric cancer patient survival.

Authors:  J A M Belien; T E Buffart; A J Gill; M A M Broeckaert; P Quirke; G A Meijer; H I Grabsch
Journal:  Br J Cancer       Date:  2009-09-15       Impact factor: 7.640

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.